Glycopyrrolate and Midazolam Interaction
Drug interaction information between Glycopyrrolate and Midazolam.
Glycopyrrolate and Midazolam have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Glycopyrrolate and Midazolam. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
These drugs do not have any known harmful interactions when used together during surgery or anesthesia.
What To Do
This combination is considered safe to use, and no special changes are needed.
FDA Label Information
No significant adverse interactions with commonly used premedications or drugs used during anesthesia and surgery (including atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, d-tubocurarine, succinylcholine and other nondepolarizing muscle relaxants) or topical local anesthetics (including lidocaine, dyclonine HCl and Cetacaine) have been observed in adults or pediatric patients.
Midazolam Also Interacts With
- Darunavir major
- Itraconazole major
- Nirmatrelvir/Ritonavir major
- Ketoconazole moderate
- Verapamil moderate
Frequently Asked Questions
Can I take Glycopyrrolate and Midazolam together?
This is a minor interaction. This combination is considered safe to use, and no special changes are needed.
How serious is the interaction between Glycopyrrolate and Midazolam?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Glycopyrrolate and Midazolam interact?
These drugs do not have any known harmful interactions when used together during surgery or anesthesia.
Understanding the Glycopyrrolate and Midazolam Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Glycopyrrolate belongs to the Long-Acting Muscarinic Antagonist (LAMA) class and Midazolam belongs to the Benzodiazepine class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: These drugs do not have any known harmful interactions when used together during surgery or anesthesia. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Glycopyrrolate has 2 total documented interactions on file in this dataset, and Midazolam has 39. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: This combination is considered safe to use, and no special changes are needed. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Glycopyrrolate or Midazolam based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.